Boehringer Ingelheim Corporation Release: New Data show Striverdi® (olodaterol)* Respimat® Improves Exercise Tolerance in Patients With Moderate to Very Severe COPD1  
10/29/2013 10:22:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The latest data from Phase III studies show that treatment with once-daily olodaterol Respimat® resulted in statistically significant improvements in the amount of time that patients with chronic obstructive pulmonary disease (COPD) could exercise before breathlessness forced them to stop.

Help employers find you! Check out all the jobs and post your resume.